Langerhans Cell Histiocytosis (LCH): Guidelines for Diagnosis, Clinical Work-Up, and Treatment for Patients Till the Age of 18 Years
By R. Haupt, M. Minkov, I. Astigarraga, E. Schäfer, V. Nanduri, R. Jubran, R. Egeler, G. Janka, D. Mićić, C. Rodríguez-Galindo and 4 more. Pediatric Blood & Cancer, 2012
610 citations recorded by the source corpus.
These guidelines for the management of patients up to 18 years with Langerhans cell histiocytosis (LCH) have been set up by a group of experts involved in the Euro Histio Net project who participated in national or international studies and in peer reviewed publications. Existing guidelines were reviewed and changed where new evidence was available in the literature up to 2012. Data and publications have been ranked according to evidence based medicine and when there was a lack of published data, consensus between experts was sought. Guidelines for diagnosis, initial clinical work‐up, and treatment and long‐term follow‐up of LCH patients are presented. Pediatr Blood Cancer 2013;60:175–184. © 2012 The Authors. Pediatric Blood & Cancer, published by Wiley Periodicals, Inc.
Subfields: Infectious Diseases, Physiology, Surgery
View Paper: https://www.semanticscholar.org/paper/e233b8854559afe93135ae696e15e7c06a01da8e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- A. Horne
- J. Emile
- C. Allen
- M. Jordan
- O. Abla
- S. Fraitag
- R. Egeler
- J. Henter
Citations in the corpus
- Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. (2016, methodology): “In the diagnostic workup of LCH, several diagnoses should be excluded, depending on the anatomic localization of the disease.(15) Differential pathological diagnosiswith indeterminate cell histiocytosis (ICH) is based on the absence of CD207 expression on this latter entity.”